http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ha Ra Gu,Su Cheol Park,Su Jin Choi,Jae Cheol Lee,You Cheoul Kim,Chul Ju Han,Ki Young Yang,김연주,Geum Youb Noh,So Hyeon No,Jae-Hoon Jeong 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.1
Background/Aims: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells. Methods: Several different human HCC cell lines were used to test the growth-inhibiting effects and cell toxicity of silibinin both alone and in combination with either gefitinib or sorafenib. The cell viability and growth inhibition were assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, trypan blue staining, and a colony-forming assay. Furthermore, changes in epidermal growth factor receptor (EGFR)-related signals were evaluated by Western blot analysis. Results: Gefitinib, sorafenib, and silibinin individually exhibited dose-dependent antiproliferative effects on HCC cells. Combined treatment with silibinin enhanced the gefitinib-induced growth-inhibiting effects in some HCC cell lines. The combination effect of gefitinib and silibinin was synergistic in the SNU761 cell line, but was only additive in the Huh-BAT cell line. The combination effect may be attributable to inhibition of EGFR-dependent Akt signaling. Enhanced growth-inhibiting effects were also observed in HCC cells treated with a combination of sorafenib and silibinin. Conclusions: Combined treatment with silibinin enhanced the growth-inhibiting effects of both gefitinib and sorafenib. Therefore, the combination of silibinin with either sorafenib or gefitinib could be a useful treatment approach for HCC in the future. (Clin Mol Hepatol 2015;21:49-59)
( Ha Ra Gu ),( Su Cheol Park ),( Su Jin Choi ),( Jae Cheol Lee ),( You Cheoul Kim ),( Chul Ju Han ),( Jin Kim ),( Ki Young Yang ),( Yeon Joo Kim ),( Geum Youb Noh ),( So Hyeon No ),( Jae Hoon Jeong ) 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.1
Background/Aims: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells. Methods: Several different human HCC cell lines were used to test the growth-inhibiting effects and cell toxicity of silibinin both alone and in combination with either gefitinib or sorafenib. The cell viability and growth inhibition were assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, trypan blue staining, and a colony-forming assay. Furthermore, changes in epidermal growth factor receptor (EGFR)-related signals were evaluated by Western blot analysis. Results: Gefitinib, sorafenib, and silibinin individually exhibited dose-dependent antiproliferative effects on HCC cells. Combined treatment with silibinin enhanced the gefitinib-induced growth-inhibiting effects in some HCC cell lines. The combination effect of gefitinib and silibinin was synergistic in the SNU761 cell line, but was only additive in the Huh-BAT cell line. The combination effect may be attributable to inhibition of EGFR-dependent Akt signaling. Enhanced growth-inhibiting effects were also observed in HCC cells treated with a combination of sorafenib and silibinin. Conclusions: Combined treatment with silibinin enhanced the growth-inhibiting effects of both gefitinib and sorafenib. Therefore, the combination of silibinin with either sorafenib or gefitinib could be a useful treatment approach for HCC in the future. (Clin Mol Hepatol 2015;21:49-59)
Eun-Ha Kim,Soo-Yun Park,So-Ra Jin,Sang-Gu Lee,Hyoun-Min Park,Oh-Suk Yu,Yun-Young Kang,Min-Ho Lee,Tae-Hun Ryu,Young-Soo Chung,Seon-Woo Oh 한국식품영양과학회 2021 한국식품영양과학회 학술대회발표집 Vol.2021 No.10
Untargeted metabolomics approaches offer advantages to characterize substantial equivalence among transgenic and nontransgenic crops. To investigate the substantial equivalence of PfFAD3-1 transgenic soybean lines expressing omega-3 fatty acid desaturase 3-1 gene (FAD3-1) of Physaria, profiles of hydrophillic metabolites were obtained using a GC-TOFMS in the three PfFAD3-1 lines and nontransgenic conventional varieties cultivated at Jeonju and Gunwi in 2020. In total, 40 metabolites were identified including organic acids, amino acid, and sugars. The level of ferulic acid was significantly higher in each PfFAD3-1 line compared to its direct counterpart, and the ferulic acid means of PfFAD3-1 lines were not presented in the range of reference lines. The principal components analysis showed a clear separation in the metabolite profiling between cultivation locations, indicating that the metabolic compositions in Soybean seeds could be more altered by environment rather than by genotype alone. It was suggested to include more reference varieties and cultivation years to assess the altered change in the levels of ferulic acid in PfFAD3-1 lines in relation to natural variation.
이상구(Sang-Gu Lee),오선우(Seon-Woo Oh),박수윤(Soo-Yun Park),박현민(Hyoun-Min Park),김은하(Eun-Ha Kim),진소라(So-Ra Jin),류태훈(Tae-Hun Ryu) 한국식물생명공학회 2021 JOURNAL OF PLANT BIOTECHNOLOGY Vol.48 No.4
To ensure the safety of developing or importing genetically modified organisms (GMOs), Korea has enacted the “LMO Act.” Accordingly, the safety of using GMOs as food or feed is evaluated in accordance with the concept of “substantial equivalence” proposed by OECD. The allergenicity of GMOs is assessed as a part of their safety evaluation. The methods of allergenicity assessment have been discussed by various international organizations, such as the OECD, FAO, and WHO. The main methods used for the allergenicity assessment of proteins newly expressed in GMOs include assessment of the physicochemical stability of these proteins, evaluation of their amino acid homology with existing allergenic proteins, and serum screening. In this study, we describe guidelines and related studies for the allergenicity assessment of GM crops.
Insect Juvenile Hormone Mimics from Plant Essential Oils
Kyu baik Ha,Dong Hwan Park,Seok-Hee Lee,Jong Hoon Kim,Ying Fang,Min Gu Park,Ra Mi Woo,Woo Jin Kim,Il-Kwon Park,Jae Young Choi,Yeon Ho Je 한국응용곤충학회 2016 한국응용곤충학회 학술대회논문집 Vol.2016 No.10
Insect growth regulators (IGRs) are attractive pest control agents due to their high target specificity and relative safety to the environment. Recently, plants have been shown to synthesize IGRs that affect the insect juvenile hormone (JH) as a part of their defense mechanisms. We identified several JH agonists (JHAs) and antagonists (JHANs) from plant essential oil compounds using a yeast two-hybrid system transformed with the Aedes aegypti JH receptor as a reporter system. They showed high mosquitocidal activities with relatively low LC50 values and caused retardation of ovarian development in female mosquitoes. While the JHAs increased the expression of JH-induced gene, the JHANs caused reduction in the expression of the same gene. The compounds identified in this study could provide insights on the plant-insect interactions and may be useful for the development of novel IGR insecticides.